Polatuzumab Vedotin Clinical Trials (2026): 80 Studies for Diffuse Large B-Cell Lymphoma & Diffuse Large B Cell Lymphoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
80 Polatuzumab Vedotin clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 46 indications (including Diffuse Large B-Cell Lymphoma & Diffuse Large B Cell Lymphoma) and 11,179 total planned enrollment. 7 Phase 3 Polatuzumab Vedotin trials and 44 Phase 2 are listed. 43 Polatuzumab Vedotin clinical trials are actively recruiting at 232 U.S. sites across 42 states. Most recent activity: NCT06043674 (Jan 2033).
Where to Participate: All Polatuzumab Vedotin Trial Sites in the U.S. (232 sites across 42 states)
Every actively recruiting Polatuzumab Vedotintrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University Hospital (University Of Alabama Hospital) | Birmingham35233 | NCT04884035 | Map |
| AL | Infirmary Cancer Care ( Site 0157) | Mobile36607 | NCT06890884 | Map |
| AZ | Ironwood Cancer & Research Centers ( Site 0204) | Chandler85224 | NCT06890884 | Map |
| AZ | Palo Verde Cancer Specialists ( Site 0105) | Glendale85304 | NCT06890884 | Map |
| AZ | City of Hope - Phoenix ( Site 0202) | Goodyear85338 | NCT06890884 | Map |
| AZ | Mayo Clinic - Arizona | Scottsdale85259 | NCT04884035 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT05633615 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT05633615 | Map |
| AR | Highlands Oncology Group - Fayetteville | Fayetteville72703 | NCT05633615 | Map |
| AR | Genesis Cancer and Blood Institute ( Site 0193) | Hot Springs71913 | NCT06890884 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT05633615 | Map |
| AR | Highlands Oncology Group - Rogers | Rogers72758 | NCT05633615 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT05633615 | Map |
| CA | Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135) | Burbank91505 | NCT06890884 | Map |
| CA | University of California San Francisco - Fresno Center for Medical Education and Research | Clovis93611 | NCT04970901 | Map |
| CA | UC Irvine Health Cancer Center-Newport | Costa Mesa92627 | NCT05633615 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06015880 | Map |
| CA | City of Hope Comprehensive Cancer Center ( Site 0191) | Duarte91010 | NCT06890884 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06453044 | Map |
| CA | City Of Hope National Medical Center | Duarte91010 | NCT04884035 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT05633615 | Map |
| CA | UCI Health Laguna Hills | Laguna Hills92653 | NCT05633615 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05633615 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06015880 | Map |
| CA | Scripps Health - Prebys Cancer Center | San Diego92103 | NCT04970901 | Map |
| CA | UCSF Medical Center-Parnassus | San Francisco94143 | NCT05633615 | Map |
| CA | Bass Medical Group ( Site 0123) | Walnut Creek94598 | NCT06890884 | Map |
| CO | Rocky Mountain Cancer Centers (RMCC) ( Site 8001) | Aurora80012 | NCT06890884 | Map |
| CO | Colorado West Healthcare System-Grand Valley Oncology ( Site 0165) | Grand Junction81505 | NCT06890884 | Map |
| CT | Yale University School of Medicine /ID# 242089 | New Haven06510 | NCT05283720 | Map |
| DE | Christiana Care Health Service /ID# 242301 | Newark19713 | NCT05283720 | Map |
| DE | Medical Oncology Hematology Consultants (MOHC) ( Site 8007) | Newark19713 | NCT06890884 | Map |
| DC | Georgetown University Medical Center ( Site 0117) | Washington D.C.20007 | NCT06890884 | Map |
| FL | Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130) | Boca Raton33486 | NCT06890884 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT05633615 | Map |
| FL | Baptist MD Anderson Cancer Center ( Site 0176) | Jacksonville32207 | NCT06890884 | Map |
| FL | Mayo Clinic Jacksonville - PPDS | Jacksonville32224 | NCT04884035 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT04970901 | Map |
| FL | Sylvester Comprehensive Cancer Center | Miami33136 | NCT04970901 | Map |
| FL | University of Miami | Miami33136 | NCT05260957 | Map |
| FL | University of Miami | Miami33136 | NCT06730542 | Map |
| FL | University of Miami Sylvester Cancer Center | Miami33136 | NCT05800366 | Map |
| FL | Mount Sinai Braman Comprehensive Cancer Center ( Site 0140) | Miami Beach33140 | NCT06890884 | Map |
| FL | Mid Florida Hematology and Oncology Center ( Site 0152) | Orange City32763 | NCT06890884 | Map |
| FL | Memorial Cancer Institute - Memorial Hospital West | Pembroke Pines33028 | NCT04970901 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06015880 | Map |
| FL | Tampa General Hospital /ID# 246748 | Tampa33606 | NCT05283720 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT05633615 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT05633615 | Map |
| GA | The Blood and Marrow Transplant Group of Georgia | Atlanta30342 | NCT04970901 | Map |
| GA | Winship Cancer Institute at Emory University | Atlanta30322 | NCT06043674 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30322 | NCT04970901 | Map |
| GA | Northwest Georgia Oncology Centers PC | Marietta30060 | NCT04884035 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05633615 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05633615 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05633615 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05633615 | Map |
| ID | Beacon Cancer Care ( Site 0142) | Post Falls83854 | NCT06890884 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05633615 | Map |
| IL | Northwestern University | Chicago60611 | NCT06015880 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05633615 | Map |
| IL | University of Chicago Medical Center ( Site 0126) | Chicago60637 | NCT06890884 | Map |
| IL | University of Illinois | Chicago60612 | NCT05633615 | Map |
| IL | Illinois Cancer Care ( Site 7005) | Peoria61615 | NCT06890884 | Map |
| IA | Mission Cancer + Blood - Mission Cancer Foundation | Des Moines50309 | NCT04970901 | Map |
| IA | University of Iowa-Holden Comprehensive Cancer Center ( Site 0139) | Iowa City52242 | NCT06890884 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05633615 | Map |
| IA | Mission Blood & Cancer Care ( Site 0114) | Waukee50263 | NCT06890884 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT05633615 | Map |
| KS | University Of Kansas Medical Center | Kansas City66160 | NCT04884035 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT05633615 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT05633615 | Map |
| KS | Cancer Center Of Kansas-Wichita | Wichita67214 | NCT04884035 | Map |
| KY | Saint Elizabeth Medical Center Edgewood ( Site 0141) | Edgewood41017 | NCT06890884 | Map |
| KY | Baptist Health Hardin ( Site 0154) | Elizabethtown42701 | NCT06890884 | Map |
| KY | Baptist Health Lexington ( Site 0127) | Lexington40503 | NCT06890884 | Map |
| KY | Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0185) | Louisville40207 | NCT06890884 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05633615 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05633615 | Map |
| LA | Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180) | Baton Rouge70808 | NCT06890884 | Map |
| LA | Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209) | Monroe71202 | NCT06890884 | Map |
| LA | Ochsner Clinic Foundation ( Site 0189) | New Orleans70121 | NCT06890884 | Map |
| LA | Louisiana State University Health Sciences Shreveport ( Site 0195) | Shreveport71103 | NCT06890884 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05633615 | Map |
| MD | University of Maryland, Baltimore /ID# 242218 | Baltimore21201 | NCT05283720 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT05633615 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT04970901 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05800366 | Map |
| MA | Brigham and Women's Hospital | Boston02215 | NCT06043674 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05800366 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06043674 | Map |
| MA | Dana Farber Cancer Institute ( Site 0111) | Boston02215 | NCT06890884 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04970901 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT05633615 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05633615 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT05633615 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT05633615 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT05633615 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT05633615 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT05633615 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT05633615 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT05633615 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT05633615 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT05633615 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT05633615 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT05633615 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT05633615 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT05633615 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT05633615 | Map |
| MN | Minnesota Oncology Hematology (MNO) ( Site 8004) | Burnsville55337 | NCT06890884 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT04970901 | Map |
| MN | Mayo Clinic - Rochester | Rochester55905-0001 | NCT04884035 | Map |
| MN | HealthPartners Cancer Research Center | Saint Louis Park55426 | NCT04884035 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06040320 | Map |
| MT | Bozeman Health Deaconess Hospital ( Site 0183) | Bozeman59715 | NCT06890884 | Map |
| NE | NHO Revive Research Institute, LLC ( Site 0121) | Lincoln68506 | NCT06890884 | Map |
| NE | University of Nebraska - Fred and Pamela Buffet Center | Omaha68198 | NCT04884035 | Map |
| NE | University Of Nebraska Medical Center ( Site 0110) | Omaha68198 | NCT06890884 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT05633615 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06765317 | Map |
| NJ | Hackensack Meridian Health (Data collection only) | Hackensack07601 | NCT06765317 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06765317 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06765317 | Map |
| NJ | Atlantic Health Morristown Medical Center ( Site 0163) | Morristown07960 | NCT06890884 | Map |
| NJ | Valley Health Systems - Ridgewood Campus ( Site 0125) | Paramus07652 | NCT06890884 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT05633615 | Map |
| NY | Erie County Medical Center ( Site 0175) | Buffalo14215 | NCT06890884 | Map |
| NY | Roswell Park Cancer Institute ( Site 0192) | Buffalo14263 | NCT06890884 | Map |
| NY | Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT06765317 | Map |
| NY | Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison10604 | NCT06765317 | Map |
| NY | Northwell Health - Monter Cancer Center /ID# 245435 | Lake Success11042 | NCT05283720 | Map |
| NY | Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0208) | Mineola11501 | NCT06890884 | Map |
| NY | Columbia University Irving Medical Center | New York10027 | NCT04970901 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT04679012 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 242123 | New York10029 | NCT05283720 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108) | New York10016 | NCT06890884 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT06765317 | Map |
| NY | Mount Sinai- Icahn School of Medicine | New York10029 | NCT04679012 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT05633615 | Map |
| NY | Weill Cornell Medicine | New York10065 | NCT04679012 | Map |
| NY | University of Rochester | Rochester14642 | NCT05633615 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Rockville Centre11553 | NCT06765317 | Map |
| NY | SUNY Upstate Cancer Center ( Site 0178) | Syracuse13210 | NCT06890884 | Map |
| NY | New York Medical Center | Valhalla10595 | NCT04491370 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT05633615 | Map |
| NY | Clinical Research Alliance ( Site 0122) | Westbury11590 | NCT06890884 | Map |
| NC | The University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT06043674 | Map |
| NC | University of North Carolina Medical Center ( Site 0136) | Chapel Hill27514 | NCT06890884 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05633615 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT04884035 | Map |
| NC | Novant Health Presbyterian Medical Center ( Site 0177) | Charlotte28204 | NCT06890884 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT05633615 | Map |
| NC | East Carolina University - Brody School of Medicine /ID# 242506 | Greenville27834 | NCT05283720 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27157 | NCT04884035 | Map |
| NC | Novant Health Forsyth Medical Center ( Site 0206) | Winston-Salem27103 | NCT06890884 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05633615 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT06015880 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05633615 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05633615 | Map |
| OH | University of Cincinnati Medical Center ( Site 0156) | Cincinnati45219 | NCT06890884 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05633615 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT06015880 | Map |
| OH | Cleveland Clinic Main ( Site 0101) | Cleveland44195 | NCT06890884 | Map |
| OH | Cleveland Clinic Main Campus | Cleveland44195 | NCT04970901 | Map |
| OH | Fairview Hospital-Moll Cancer Center ( Site 0198) | Cleveland44111 | NCT06890884 | Map |
| OH | University Hospitals of Cleveland ( Site 0155) | Cleveland44106 | NCT06890884 | Map |
| OH | Ohio state University | Columbus43210 | NCT04679012 | Map |
| OH | The Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06043674 | Map |
| OH | Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0199) | Mayfield Heights44124 | NCT06890884 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05633615 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06015880 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05633615 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05633615 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT04970901 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05633615 | Map |
| OR | Providence Oncology and Hematology Clinic Westside ( Site 0179) | Portland97225 | NCT06890884 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05633615 | Map |
| OR | Providence Portland Medical Center ( Site 0120) | Portland97213 | NCT06890884 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05633615 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05633615 | Map |
| PA | Penn Medicine - Perelman Center for Advanced Medicine | Philadelphia19104 | NCT04970901 | Map |
| PA | Temple University Hospital ( Site 0133) | Philadelphia19140 | NCT06890884 | Map |
| PA | University of Pennsylvania/Abramson Cancer Center | Philadelphia19104 | NCT05633615 | Map |
| PA | Alliance Cancer Specialists (ACS) ( Site 8010) | Sellersville18960 | NCT06890884 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT05633615 | Map |
| PA | Cancer Care Associates Of York ( Site 0174) | York17403 | NCT06890884 | Map |
| RI | Brown University Health - Rhode Island Hospital | Providence02903 | NCT04970901 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT05633615 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05633615 | Map |
| SC | Medical University of South Carolina ( Site 0153) | Charleston29425 | NCT06890884 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT05633615 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT05633615 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT05633615 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT05633615 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT05633615 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT05633615 | Map |
| TN | Tennessee Cancer Specialists ( Site 7004) | Knoxville37909 | NCT06890884 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT05633615 | Map |
| TN | Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) | Nashville37203 | NCT04970901 | Map |
| TN | SCRI Oncology Partners ( Site 7002) | Nashville37203 | NCT06890884 | Map |
| TX | Texas Oncology - West Texas ( Site 8008) | Amarillo79124 | NCT06890884 | Map |
| TX | Texas Oncology - Central/South Texas ( Site 8006) | Austin78705 | NCT06890884 | Map |
| TX | Baylor University Medical Center | Dallas75246 | NCT04970901 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05615636 | Map |
| TX | MD Anderson Cancer Center | Houston77003 | NCT04884035 | Map |
| TX | Texas Oncology - Northeast Texas ( Site 8002) | Palestine75801 | NCT06890884 | Map |
| TX | Texas Oncology - San Antonio ( Site 8009) | San Antonio78240 | NCT06890884 | Map |
| UT | Intermountain Medical Center ( Site 0182) | Murray84107 | NCT06890884 | Map |
| UT | Intermountain Medical Oncology | Murray84107 | NCT04884035 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT04970901 | Map |
| UT | Intermountain Cancer Center - St George | St. George84790 | NCT04884035 | Map |
| UT | Intermountain Healthcare - St. George ( Site 0203) | St. George84790 | NCT06890884 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05633615 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT05633615 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT05633615 | Map |
| VA | Emily Couric Clinical Cancer Center | Charlottesville22903 | NCT04970901 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06015880 | Map |
| VA | Virginia Cancer Specialists, PC ( Site 8003) | Manassas20110 | NCT06890884 | Map |
| VA | VCU Health Adult Outpatient Pavillion ( Site 0138) | Richmond23219 | NCT06890884 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05633615 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT04231877 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT05455697 | Map |
| WA | Swedish Medical Center - Seattle /ID# 242269 | Seattle98104 | NCT05283720 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05633615 | Map |
| WA | Northwest Cancer Specialists (Compass Oncology) ( Site 8000) | Vancouver98684 | NCT06890884 | Map |
| WI | SSM Health Dean Medical Group ( Site 0106) | Madison53715 | NCT06890884 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05633615 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05633615 | Map |
| WI | Froedtert & Medical College of Wisconsin | Milwaukee53226 | NCT04970901 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05633615 | Map |
| WI | Medical College of Wisconsin ( Site 0103) | Milwaukee53226 | NCT06890884 | Map |
| WI | Froedtert and MCW Moorland Reserve Health Center | New Berlin53151 | NCT05633615 | Map |
Polatuzumab Vedotin clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 5 | 2 | 2 | 1 | 10 | ||||
| P1/P2 | 3 | 3 | 8 | 2 | 1 | 17 | |||
| P2 | 20 | 5 | 1 | 1 | 2 | 1 | 12 | 2 | 44 |
| P3 | 1 | 2 | 3 | 1 | 7 | ||||
| N/A | 1 | 1 | 2 |
Recruiting Polatuzumab Vedotin clinical trials (43)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | P2 | Chronic Lymphocytic Leukemia | 70 | Jan 2024 |
| NCT06890884 | MK-2140A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | P2 | Lymphoma, Large B-Cell, Diffuse | 594 | Apr 2025 |
| NCT05283720 | SCA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | P2 | Non-Hodgkin Lymphoma | 496 | Jun 2022 |
| NCT06040320 | RPolatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) | P1/P2 | Post-transplant Lymphoproliferative Disorder | 12 | Oct 2023 |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | P1 | Aggressive Non-Hodgkin Lymphoma | 56 | Oct 2020 |
| NCT07184788 | G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma | P2 | Aggressive B-Cell Lymphoma | 80 | Oct 2025 |
| NCT07415980 | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL | P1/P2 | Double Expressor DLBCL | 68 | Apr 2026 |
| NCT06664411 | Pola-ZR2P in Previously Untreated DLBCL | P2 | Diffuse Large B-cell Lymphoma | 80 | Sep 2024 |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | Diffuse Large B-Cell Lymphoma | 396 | Jun 2023 |
| NCT06730542 | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma | P1 | CNS Lymphoma | 20 | Apr 2025 |
| NCT06665217 | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | P2 | Diffuse Large B-Cell Lymphoma | 80 | Sep 2025 |
| NCT06594939 | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma | P2 | Diffuse Large B Cell Lymphoma (DLBCL) | 31 | Jun 2026 |
| NCT07594899 | GUIDANCE-10AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | P2 | Large B-Cell Lymphoma (LBCL) | 178 | May 2026 |
| NCT07514169 | SILVERGLOThe Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL | P2 | Large B-Cell Lymphoma (LBCL) | 30 | Mar 2026 |
| NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | P2 | DLBCL - Diffuse Large B Cell Lymphoma | 134 | Jun 2025 |
| NCT07502872 | TPGTPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | P2 | Diffuse Large B Cell Lymphoma | 30 | May 2026 |
| NCT05800366 | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | P2 | Lymphoma | 41 | Apr 2023 |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | P3 | Diffuse Large B-Cell Lymphoma | 100 | Jul 2024 |
| NCT06516978 | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | P2 | Diffuse Large B Cell Lymphoma | 528 | Oct 2024 |
| NCT06803693 | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | P2 | Diffuse Large B-Cell Lymphoma | 152 | Apr 2025 |
| NCT05260957 | NHLCAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | P2 | Refractory Non-Hodgkin Lymphoma | 22 | Dec 2022 |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | P2 | Diffuse Large B-Cell Lymphoma (DLBCL) | 58 | Jan 2026 |
| NCT04884035 | CC-220Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | P1 | Lymphoma, B-Cell | 224 | Sep 2021 |
| NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P2 | DLBCL - Diffuse Large B Cell Lymphoma | 40 | Jan 2026 |
| NCT06554600 | A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | Refractory or Relapsed Diffuse Large B Cell Lymphoma | 36 | Aug 2024 |
| NCT06071871 | PORTALA Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | P2 | Large B-cell Lymphoma | 99 | Aug 2024 |
| NCT06468943 | Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | P2 | Effects of Chemotherapy | 20 | Jul 2023 |
| NCT06453044 | Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma | P2 | Recurrent Grade 1 Follicular Lymphoma | 41 | Sep 2024 |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | P2 | Diffuse Large B Cell Lymphoma (DLBCL) | 42 | Jan 2025 |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | P2 | Diffuse Large B-Cell Lymphoma | 152 | Dec 2024 |
| NCT07001540 | DLBCLEvaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation | P2 | Diffuse Large B-Cell Lymphoma | 130 | May 2025 |
| NCT04970901 | LOTIS-7A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | P1 | B-Cell Non-Hodgkin Lymphoma | 200 | Jun 2022 |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | P2 | Diffuse Large B Cell Lymphoma | 30 | Oct 2023 |
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | P2 | Richter Syndrome | 20 | Sep 2021 |
| NCT04913103 | CLSGMCLPOLAStudy of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL | P2 | Lymphoma, Mantle-Cell | 21 | Sep 2021 |
| NCT05615636 | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | P2 | Hodgkin Lymphoma | 36 | Apr 2023 |
| NCT07122609 | Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | Relapsed and Refractory DLBCL | 22 | Aug 2025 |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | P1/P2 | B-cell Lymphoma | 20 | Aug 2021 |
| NCT05455697 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | P1/P2 | Diffuse Large B-Cell Lymphoma | 35 | Jan 2023 |
| NCT06015880 | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P1 | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 30 | May 2024 |
| NCT05868395 | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | P2 | Mantle-cell Lymphoma | 16 | Jan 2024 |
| NCT06530511 | PROPolatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | P2 | Diffuse Large B Cell Lymphoma | 30 | Aug 2024 |
| NCT07012980 | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | P2 | Diffuse Large B-Cell Lymphoma | 38 | Jun 2025 |
Polatuzumab Vedotin clinical trials by indication
Diffuse Large B-Cell Lymphoma (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05633615 | — | P2 | recruiting | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT06665217 | — | P2 | not yet recruiting | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma |
| NCT06522555 | — | P3 | recruiting | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma |
| NCT06803693 | — | P2 | recruiting | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL |
| NCT06441097 | — | P2 | not yet recruiting | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL |
| NCT07001540 | DLBCL | P2 | recruiting | Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation |
| NCT05455697 | — | P1/P2 | recruiting | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma |
| NCT05954910 | — | N/A | active not recruiting | A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma |
| + 4 more, see All trials below. | ||||
Diffuse Large B Cell Lymphoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07502872 | TPG | P2 | not yet recruiting | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma |
| NCT06516978 | — | P2 | not yet recruiting | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL |
| NCT06176729 | — | P2 | recruiting | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients |
| NCT06530511 | PRO | P2 | recruiting | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL |
| NCT05940064 | — | P2 | unknown | Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma |
| NCT05940051 | — | P2 | unknown | Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT04914741 | COALITION | P1/P2 | active not recruiting | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) |
| NCT04535102 | — | P2 | withdrawn | POLA+BR for Relapsed or Refractory DLBCL |
Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04739813 | — | P1 | active not recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma |
| NCT05800366 | — | P2 | recruiting | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma |
| NCT02257567 | DCDS4501A | P1/P2 | completed | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma |
| NCT02729896 | FL | P1/P2 | completed | A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
Lymphoma, Large B-Cell, Diffuse (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06890884 | MK-2140 | P2 | recruiting | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) |
| NCT05798156 | R-Pola-Glo | P2 | active not recruiting | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
| NCT04790903 | R | P1 | terminated | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) |
Diffuse Large B-cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06664411 | — | P2 | recruiting | Pola-ZR2P in Previously Untreated DLBCL |
| NCT05498220 | — | P2 | terminated | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| NCT03677154 | BTCT4465A | P1/P2 | completed | Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma |
Non-Hodgkin Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05283720 | SC | P2 | recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma |
| NCT05171647 | SUNMO | P3 | active not recruiting | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma |
| NCT05169658 | — | P2 | completed | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma |
Diffuse Large B Cell Lymphoma (DLBCL) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06594939 | — | P2 | not yet recruiting | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma |
| NCT06765317 | — | P2 | recruiting | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma |
Large B-Cell Lymphoma (LBCL) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07594899 | GUIDANCE-10 | P2 | not yet recruiting | AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL |
| NCT07514169 | SILVERGLO | P2 | recruiting | The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL |
Diffuse Large B-Cell Lymphoma (DLBCL) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07397832 | — | P2 | recruiting | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL |
| NCT04624893 | — | N/A | unknown | A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin |
DLBCL - Diffuse Large B Cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07034508 | — | P2 | not yet recruiting | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 |
| NCT07231250 | — | P2 | not yet recruiting | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma |
Lymphoma, B-Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04882163 | CC-220 | P1/P2 | withdrawn | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma |
| NCT04884035 | CC-220 | P1 | recruiting | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma |
B-cell Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03671018 | BTCT4465A | P1/P2 | active not recruiting | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma |
| NCT03677141 | BTCT4465A | P1/P2 | completed | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma |
Non-Hodgkins Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03533283 | — | P1/P2 | active not recruiting | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma |
| NCT01290549 | — | P1 | completed | A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma |
Double Expressor DLBCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07415980 | — | P1/P2 | not yet recruiting | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL |
Aggressive B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07184788 | — | P2 | not yet recruiting | G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma |
Relapsed and Refractory DLBCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07122609 | — | P2 | not yet recruiting | Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
CNS Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06730542 | — | P1 | recruiting | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma |
Recurrent Grade 1 Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06453044 | — | P2 | recruiting | Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma |
Refractory or Relapsed Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06554600 | — | P2 | recruiting | A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06071871 | PORTAL | P2 | recruiting | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma |
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06015880 | — | P1 | recruiting | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06043674 | — | P2 | recruiting | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation |
Mantle-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05868395 | — | P2 | recruiting | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma |
Post-transplant Lymphoproliferative Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06040320 | R | P1/P2 | recruiting | Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) |
Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06047080 | — | P3 | active not recruiting | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma |
Effects of Chemotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06468943 | — | P2 | enrolling by invitation | Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05615636 | — | P2 | recruiting | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL |
Refractory Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05260957 | NHL | P2 | recruiting | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). |
Lymphoma, Follicular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05410418 | — | P2 | active not recruiting | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma |
B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04970901 | LOTIS-7 | P1 | recruiting | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) |
Richter Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04679012 | — | P2 | recruiting | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation |
DLBCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04594798 | — | P2 | active not recruiting | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL |
Lymphoma, Mantle-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04913103 | CLSGMCLPOLA | P2 | not yet recruiting | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL |
B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04491370 | — | P1/P2 | recruiting | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma |
Relapsed Diffuse Large B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04833114 | Pola-R-ICE | P3 | completed | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) |
Recurrent B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04659044 | — | P2 | terminated | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
Diffuse Large B-Cell Lymphoma Unclassifiable (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04665765 | — | P2 | active not recruiting | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04607772 | RR | P1/P2 | withdrawn | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) |
Aggressive Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04231877 | — | P1 | recruiting | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma |
Diffuse, Large B-Cell, Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04236141 | — | P3 | terminated | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). |
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04323956 | — | P1 | active not recruiting | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma |
B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03467373 | CHOP | P1 | completed | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL |
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02600897 | FL | P1/P2 | completed | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02611323 | FL | P1/P2 | completed | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) |
Lymphoma, Non Hodgkin (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01992653 | — | P1/P2 | completed | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma |
Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01691898 | ROMULUS | P1/P2 | completed | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) |
Polatuzumab Vedotin pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SUNMO | NCT05171647 | P3 | active not recruiting | Non-Hodgkin Lymphoma | 208 | PMID 41037766 |
| POLARIX | NCT03274492 | P3 | completed | Diffuse Large B-Cell Lymphoma | 1,000 | PMID 35726803 |
| Pola-R-ICE | NCT04833114 | P3 | completed | Relapsed Diffuse Large B-cell Lymphoma | 306 | — |
| POLARGO | NCT04182204 | P3 | completed | Diffuse Large B-Cell Lymphoma | 270 | — |
| MK-2140 | NCT06890884 | P2 | recruiting | Lymphoma, Large B-Cell, Diffuse | 594 | — |
| SC | NCT05283720 | P2 | recruiting | Non-Hodgkin Lymphoma | 496 | — |
| GUIDANCE-10 | NCT07594899 | P2 | not yet recruiting | Large B-Cell Lymphoma (LBCL) | 178 | — |
| SILVERGLO | NCT07514169 | P2 | recruiting | Large B-Cell Lymphoma (LBCL) | 30 | — |
| TPG | NCT07502872 | P2 | not yet recruiting | Diffuse Large B Cell Lymphoma | 30 | — |
| NHL | NCT05260957 | P2 | recruiting | Refractory Non-Hodgkin Lymphoma | 22 | — |
| PORTAL | NCT06071871 | P2 | recruiting | Large B-cell Lymphoma | 99 | — |
| R-Pola-Glo | NCT05798156 | P2 | active not recruiting | Lymphoma, Large B-Cell, Diffuse | 125 | — |
| DLBCL | NCT07001540 | P2 | recruiting | Diffuse Large B-Cell Lymphoma | 130 | — |
| CLSGMCLPOLA | NCT04913103 | P2 | not yet recruiting | Lymphoma, Mantle-Cell | 21 | — |
| PRO | NCT06530511 | P2 | recruiting | Diffuse Large B Cell Lymphoma | 30 | — |
Terminated and withdrawn Polatuzumab Vedotin trials (7)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04882163withdrawnStudy to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- NCT04607772withdrawnStudy of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT05498220terminatedPolatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT04790903terminatedA Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04659044terminatedPolatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- NCT04535102withdrawnPOLA+BR for Relapsed or Refractory DLBCL
- NCT04236141terminatedA Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
All Polatuzumab Vedotin trials (80)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | P2 | recruiting | 70 | Christine Ryan | Jan 2024 | |
| NCT06890884 | MK-2140 | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | P2 | recruiting | 594 | Merck Sharp & Dohme LLC | Apr 2025 |
| NCT05283720 | SC | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | P2 | recruiting | 496 | Genmab | Jun 2022 |
| NCT06040320 | R | Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) | P1/P2 | recruiting | 12 | Washington University School of Medicine | Oct 2023 |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | P1 | recruiting | 56 | University of Washington | Oct 2020 | |
| NCT07184788 | G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma | P2 | not yet recruiting | 80 | Navy General Hospital, Beijing | Oct 2025 | |
| NCT04739813 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | P1 | active not recruiting | 34 | National Cancer Institute (NCI) | Jul 2021 | |
| NCT07415980 | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL | P1/P2 | not yet recruiting | 68 | Sun Yat-sen University | Apr 2026 | |
| NCT06664411 | Pola-ZR2P in Previously Untreated DLBCL | P2 | recruiting | 80 | Navy General Hospital, Beijing | Sep 2024 | |
| NCT06047080 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | P3 | active not recruiting | 1,130 | Hoffmann-La Roche | Sep 2023 | |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | recruiting | 396 | SWOG Cancer Research Network | Jun 2023 | |
| NCT06730542 | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma | P1 | recruiting | 20 | Juan P. Alderuccio, MD | Apr 2025 | |
| NCT06665217 | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | P2 | not yet recruiting | 80 | Navy General Hospital, Beijing | Sep 2025 | |
| NCT06594939 | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma | P2 | not yet recruiting | 31 | Medical College of Wisconsin | Jun 2026 | |
| NCT07594899 | GUIDANCE-10 | AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | P2 | not yet recruiting | 178 | Ruijin Hospital | May 2026 |
| NCT07514169 | SILVERGLO | The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL | P2 | recruiting | 30 | Ruijin Hospital | Mar 2026 |
| NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | P2 | not yet recruiting | 134 | Institute of Hematology & Blood Diseases Hospital, China | Jun 2025 | |
| NCT07502872 | TPG | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | P2 | not yet recruiting | 30 | Brown University | May 2026 |
| NCT05800366 | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | P2 | recruiting | 41 | Jennifer Crombie, MD | Apr 2023 | |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | P3 | recruiting | 100 | Ruijin Hospital | Jul 2024 | |
| NCT05410418 | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | P2 | active not recruiting | 34 | Washington University School of Medicine | Oct 2022 | |
| NCT04882163 | CC-220 | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | P1/P2 | withdrawn | 0 | Celgene | Oct 2021 |
| NCT06516978 | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | P2 | not yet recruiting | 528 | The First Affiliated Hospital with Nanjing Medical University | Oct 2024 | |
| NCT06803693 | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | P2 | recruiting | 152 | Ruijin Hospital | Apr 2025 | |
| NCT05260957 | NHL | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | P2 | recruiting | 22 | Lazaros Lekakis | Dec 2022 |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | P2 | recruiting | 58 | Tianjin Medical University Cancer Institute and Hospital | Jan 2026 | |
| NCT04884035 | CC-220 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | P1 | recruiting | 224 | Celgene | Sep 2021 |
| NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P2 | not yet recruiting | 40 | Li Zhiming | Jan 2026 | |
| NCT06554600 | A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | recruiting | 36 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Aug 2024 | |
| NCT06071871 | PORTAL | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | P2 | recruiting | 99 | University College, London | Aug 2024 |
| NCT04323956 | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | P1 | active not recruiting | 50 | Mayo Clinic | Jun 2020 | |
| NCT06468943 | Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | P2 | enrolling by invitation | 20 | The First Affiliated Hospital of Soochow University | Jul 2023 | |
| NCT06453044 | Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma | P2 | recruiting | 41 | City of Hope Medical Center | Sep 2024 | |
| NCT05798156 | R-Pola-Glo | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP | P2 | active not recruiting | 125 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Mar 2023 |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | P2 | recruiting | 42 | Memorial Sloan Kettering Cancer Center | Jan 2025 | |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | P2 | not yet recruiting | 152 | Ruijin Hospital | Dec 2024 | |
| NCT07001540 | DLBCL | Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation | P2 | recruiting | 130 | Fudan University | May 2025 |
| NCT04970901 | LOTIS-7 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | P1 | recruiting | 200 | ADC Therapeutics S.A. | Jun 2022 |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | P2 | recruiting | 30 | Yan Zhang, MD | Oct 2023 | |
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | P2 | recruiting | 20 | Weill Medical College of Cornell University | Sep 2021 | |
| NCT04913103 | CLSGMCLPOLA | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL | P2 | not yet recruiting | 21 | Czech Lymphoma Study Group | Sep 2021 |
| NCT05615636 | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | P2 | recruiting | 36 | M.D. Anderson Cancer Center | Apr 2023 | |
| NCT07122609 | Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | not yet recruiting | 22 | Ruijin Hospital | Aug 2025 | |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | P1/P2 | recruiting | 20 | New York Medical College | Aug 2021 | |
| NCT05455697 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | P1/P2 | recruiting | 35 | University of Washington | Jan 2023 | |
| NCT06015880 | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P1 | recruiting | 30 | National Cancer Institute (NCI) | May 2024 | |
| NCT05954910 | A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma | — | active not recruiting | 1,000 | Hoffmann-La Roche | Aug 2023 | |
| NCT05868395 | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | P2 | recruiting | 16 | Medical University of Vienna | Jan 2024 | |
| NCT05171647 | SUNMO | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | P3 | active not recruiting | 208 | Hoffmann-La Roche | Apr 2022 |
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | P1/P2 | active not recruiting | 211 | Hoffmann-La Roche | May 2018 | |
| NCT06530511 | PRO | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | P2 | recruiting | 30 | Affiliated Hospital of Nantong University | Aug 2024 |
| NCT07012980 | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | P2 | not yet recruiting | 38 | Shanghai Zhongshan Hospital | Jun 2025 | |
| NCT04594798 | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | P2 | active not recruiting | 39 | University of Rochester | Sep 2021 | |
| NCT04479267 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | P2 | active not recruiting | 8 | Barbara Ann Karmanos Cancer Institute | Aug 2020 | |
| NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P2 | active not recruiting | 41 | City of Hope Medical Center | Jan 2021 | |
| NCT03274492 | POLARIX | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | P3 | completed | 1,000 | Hoffmann-La Roche | Nov 2017 |
| NCT05940064 | Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma | P2 | unknown | 30 | Peng Liu | Jul 2023 | |
| NCT04607772 | RR | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | withdrawn | 0 | Karyopharm Therapeutics Inc | Nov 2020 |
| NCT05940051 | Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | unknown | 35 | Peng Liu | Jul 2023 | |
| NCT04833114 | Pola-R-ICE | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) | P3 | completed | 306 | GWT-TUD GmbH | Apr 2021 |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2 | terminated | 5 | UNC Lineberger Comprehensive Cancer Center | Feb 2023 | |
| NCT03677154 | BTCT4465A | Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma | P1/P2 | completed | 188 | Hoffmann-La Roche | May 2019 |
| NCT04914741 | COALITION | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) | P1/P2 | active not recruiting | 80 | Peter MacCallum Cancer Centre, Australia | Jun 2021 |
| NCT03671018 | BTCT4465A | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | P1/P2 | active not recruiting | 422 | Hoffmann-La Roche | Sep 2018 |
| NCT05169658 | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | P2 | completed | 42 | University of Washington | Mar 2022 | |
| NCT03467373 | CHOP | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | P1 | completed | 111 | Hoffmann-La Roche | Mar 2018 |
| NCT04182204 | POLARGO | A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P3 | completed | 270 | Hoffmann-La Roche | Feb 2020 |
| NCT04790903 | R | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | P1 | terminated | 50 | Hoffmann-La Roche | Jul 2021 |
| NCT04659044 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | P2 | terminated | 3 | Academic and Community Cancer Research United | Apr 2021 | |
| NCT03677141 | BTCT4465A | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | P1/P2 | completed | 117 | Hoffmann-La Roche | Mar 2019 |
| NCT02611323 | FL | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 133 | Hoffmann-La Roche | Mar 2016 |
| NCT04535102 | POLA+BR for Relapsed or Refractory DLBCL | P2 | withdrawn | 0 | University of Colorado, Denver | Jan 2021 | |
| NCT04236141 | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). | P3 | terminated | 42 | Hoffmann-La Roche | Jul 2020 | |
| NCT02600897 | FL | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 114 | Hoffmann-La Roche | Mar 2016 |
| NCT02257567 | DCDS4501A | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | P1/P2 | completed | 331 | Hoffmann-La Roche | Oct 2014 |
| NCT04624893 | A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin | — | unknown | 35 | Jiangsu Cancer Institute & Hospital | Dec 2019 | |
| NCT02729896 | FL | A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 36 | Hoffmann-La Roche | Nov 2016 |
| NCT01691898 | ROMULUS | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | P1/P2 | completed | 231 | Genentech, Inc. | Sep 2012 |
| NCT01992653 | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | P1/P2 | completed | 85 | Genentech, Inc. | Nov 2013 | |
| NCT01290549 | A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma | P1 | completed | 95 | Genentech, Inc. | Mar 2011 |
Polatuzumab Vedotin clinical trials: frequently asked questions
- How many Polatuzumab Vedotin clinical trials are there?
- 80 Polatuzumab Vedotin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 30 are actively recruiting participants. 14 are marked completed.
- Are Polatuzumab Vedotin clinical trials recruiting in 2026?
- Yes — 30 Polatuzumab Vedotin trials are actively recruiting in 2026, with 232 U.S. sites across 42 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Polatuzumab Vedotin being studied for?
- Polatuzumab Vedotin is being studied for Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B-Cell and 105 more. The trials are grouped by indication on this page.
- What phase is Polatuzumab Vedotin in?
- Polatuzumab Vedotin clinical trials span 7 Phase 3, 44 Phase 2, 10 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Polatuzumab Vedotin clinical trials?
- The lead sponsor across the most Polatuzumab Vedotin trials is Hoffmann-La Roche, with 48 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Polatuzumab Vedotinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: